ライフサイエンスコーパス: cocaine addiction

1 est in this target as potential treatment of cocaine addiction.

2 shows promise as a treatment for people with cocaine addiction.

3 d inform the development of therapeutics for cocaine addiction.

4 t to the pathophysiologic characteristics of cocaine addiction.

5 e tendencies and relationships may pre-exist cocaine addiction.

6 a period of heightened propensity to develop cocaine addiction.

7 date could facilitate control of behavior in cocaine addiction.

8 ere are no FDA-approved medications to treat cocaine addiction.

9 ovel therapeutic target for the treatment of cocaine addiction.

10 g, making it a promising pharmacotherapy for cocaine addiction.

11 agonism as a viable therapeutic strategy for cocaine addiction.

12 Administration-approved pharmacotherapy for cocaine addiction.

13 ortant target for cue-exposure therapies for cocaine addiction.

14 es to diverse types of plasticity, including cocaine addiction.

15 ern of maladaptive behaviors associated with cocaine addiction.

16 receptors that are involved in the action of cocaine addiction.

17 stitute a risk factor for the development of cocaine addiction.

18 cluding heroin and prescription opioids, and cocaine addiction.

19 promoting long-term resistance to relapse to cocaine addiction.

20 er impair executive function and learning in cocaine addiction.

21 th cue exposure therapy for the treatment of cocaine addiction.

22 gene silencing, is involved in regulation of cocaine addiction.

23 tial treatment for both cocaine overdose and cocaine addiction.

24 tion-related behaviors in an animal model of cocaine addiction.

25 al morphology and behavior that may underlie cocaine addiction.

26 provide evidence for a key role of miRNAs in cocaine addiction.

27 be important in regulating vulnerability to cocaine addiction.

28 ls, MPH did not improve treatment outcome in cocaine addiction.

29 of miRNAs that are likely to play a role in cocaine addiction.

30 ich may provide a new rationale for treating cocaine addiction.

31 t individuals with combined heroin and crack cocaine addiction.

32 lasticity associated with the development of cocaine addiction.

33 g GLT1 as a potential therapeutic target for cocaine addiction.

34 long-term behavioral changes associated with cocaine addiction.

35 herapeutic option in the treatment of severe cocaine addiction.

36 et for drug development for the treatment of cocaine addiction.

37 eceptors, within brain regions implicated in cocaine addiction.

38 e likely to be therapeutically beneficial in cocaine addiction.

39 tial inroads for therapeutic intervention in cocaine addiction.

40 s potential medications for the treatment of cocaine addiction.

41 ting changes in neuronal function underlying cocaine addiction.

42 ontal cortex (mPFC) plays a critical role in cocaine addiction.

43 target for the development of treatments for cocaine addiction.

44 g-term depression, associative learning, and cocaine addiction.

45 dentify clusters of genes that contribute to cocaine addiction.

46 havioral and molecular mechanisms underlying cocaine addiction.

47 vide tools for the study of the mechanism of cocaine addiction.

48 sses for regulating at least some aspects of cocaine addiction.

49 ral associations, including vulnerability to cocaine addiction.

50 relapse to drug use is a primary symptom of cocaine addiction.

51 and has been hypothesized to play a role in cocaine addiction.

52 target for prospective pharmacotherapies for cocaine addiction.

53 a range of neurological disorders including cocaine addiction.

54 rget for pharmacotherapies designed to treat cocaine addiction.

55 to adaptive changes in the brain related to cocaine addiction.

56 in long-lasting relapse risk associated with cocaine addiction.

57 ons in patients with Parkinson's disease and cocaine addiction.

58 f early childhood stress in vulnerability to cocaine addiction.

59 sporter plays a key role in the mechanism of cocaine addiction.

60 ity to cocaine and may thereby contribute to cocaine addiction.

61 produce substantial adverse consequences for cocaine addiction.

62 paper describes an immunological approach to cocaine addiction.

63 apeutic cocaine vaccine for the treatment of cocaine addiction.

64 r agonists as a possible pharmacotherapy for cocaine addiction.

65 e their potential pathophysiological role in cocaine addiction.

66 may be useful pharmacotherapeutic agents for cocaine addiction.

67 lso offer a route towards gene therapies for cocaine addiction.

68 e social-emotional functional alterations in cocaine addiction.

69 g to study transcription factors involved in cocaine addiction.

70 g preclinical evidence for its impairment in cocaine addiction.

71 implicated noradrenergic (NA) dysfunction in cocaine addiction.

72 have therapeutic value for the treatment of cocaine addiction.

73 rstanding of molecular mechanisms underlying cocaine addiction.

74 ay have translational potential for treating cocaine addiction.

75 d maladaptive drug-related attention bias in cocaine addiction.

76 ntibody research to aid in the fight against cocaine addiction.

77 he understanding of the role of microglia in cocaine addiction.

78 f opiate and nicotine addiction, but not for cocaine addiction.

79 support a personalized treatment approach to cocaine addiction.

80 for the development of relapse treatment of cocaine addiction.

81 tment of disrupting mitochondrial fission in cocaine addiction.

82 complexes may be efficacious treatments for cocaine addiction.

83 ntial as an agonist therapy for treatment of cocaine addiction.

84 ovel therapeutic target for the treatment of cocaine addiction.

85 a promising drug target for the treatment of cocaine addiction.

86 , may render individuals more susceptible to cocaine addiction.

87 norectic and a candidate pharmacotherapy for cocaine addiction.

88 icant barrier to the successful treatment of cocaine addiction.

89 n may be valuable tools for the treatment of cocaine addiction.

90 tagonizing 5-HT1A autoreceptors for treating cocaine addiction.

91 harmacological strategy for the treatment of cocaine addiction.

92 of addiction endophenotypes, especially for cocaine addiction.

93 tify and develop novel pharmacotherapies for cocaine addiction.

94 ers including depression, visceral pain, and cocaine addiction.

95 mphetamine addictions, but not for heroin or cocaine addiction.

96 be a therapeutic target for the treatment of cocaine addiction.

97 idates for the development of treatments for cocaine addiction.

98 zheimer's disease, Huntington's disease, and cocaine addiction.

99 tionale supporting sleep-based therapies for cocaine addiction.

100 have therapeutic utility in the treatment of cocaine addiction.

101 te sleep-based therapeutic opportunities for cocaine addiction.

102 including stroke, motor neuron disease, and cocaine addiction.

103 ription of specific genes that contribute to cocaine addiction.

104 ent a novel drug target for the treatment of cocaine addiction.

105 ression is a potential therapeutic target in cocaine addiction.

106 mor growth and invasion, viral infection and cocaine addiction.

107 te alterations in the glutamate signaling in cocaine addiction.

108 havior and may be useful in the treatment of cocaine addiction.

109 provide novel therapeutic opportunities for cocaine addiction.

110 against cocaine be a viable prophylaxis for cocaine addiction?

111 These findings suggest that in cocaine addiction 1) activation of the corticolimbic rew

112 rticipation of thalamic dopamine pathways in cocaine addiction, a possibility that merits further inv

113 subjective effects is a cardinal symptom of cocaine addiction and a DSM-V criterion for substance ab

114 Although tolerance is a hallmark of cocaine addiction and a DSM-V criterion for substance ab

115 e a novel role for G9a in promoting comorbid cocaine addiction and anxiety and suggest that increased

116 Cocaine addiction and depression are comorbid disorders.

117 vestigated as potential therapeutics against cocaine addiction and for cognitive enhancement.

118 ld be considered for their potential role in cocaine addiction and hippocampal-mediated relapse after

119 icroRNA let-7d, which has been implicated in cocaine addiction and other neurological disorders, targ

120 Cocaine addiction and overdose have long defied specific

121 Successful immunotherapy of cocaine addiction and overdoses requires cocaine-binding

122 a critical step in developing treatment for cocaine addiction and preventing cardiac complications.

123 ave therapeutic potential for treating human cocaine addiction and preventing relapse.

124 ecture and molecular neuropathology of human cocaine addiction and provides a framework for translati

125 play an important role in sex differences in cocaine addiction and relapse.

126 is thought to be critical for expression of cocaine addiction and relapse.

127 ing efforts to find effective treatments for cocaine addiction and suggest the application of this pr

128 on resting-state functional connectivity in cocaine addiction and tested whether resting-state funct

129 s in the neuroadaptive cascade that leads to cocaine addiction and withdrawal.

130 be advantageous in immunopharmacotherapy for cocaine addiction, and for emergency cases of drug overd

131 in synaptic plasticity, dopamine signaling, cocaine addiction, and neurodegenerative disorders.

132 tially generalizable to other subgroups with cocaine addiction, and to additional substance use disor

133 eurons modulate numerous distinct aspects of cocaine addiction- and relapse-related behaviors, and po

134 al, predict choice to view cocaine images in cocaine addiction; and (ii) whether such behaviour predi

135 Cocaine addiction appears to be associated with a drug-i

136 Treatment efforts for cocaine addiction are hampered by high relapse rates.

137 Whether these two prominent features of cocaine addiction are related to each other and are medi

138 ussed with respect to the role of the BLA in cocaine addiction as well as previous studies characteri

139 cleus accumbens (NAc) has been implicated in cocaine addiction because (1) cocaine reinforcement is m

140 ent a novel pharmacotherapeutic approach for cocaine addiction because it may simultaneously function

141 ical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy.

142 be exploited to develop novel therapies for cocaine addiction, but a molecular target has not yet be

143 l-molecule therapeutic is available to treat cocaine addiction, but enzyme-based therapy to accelerat

144 terventions have been explored to counteract cocaine addiction, but to date no market-approved medica

145 g cocaine self-administration contributes to cocaine addiction by acting to facilitate subsequent coc

146 eking behavior, a defining characteristic of cocaine addiction, can be precipitated by contextual cue

147 Cocaine addiction continues to be a major health and soc

148 Cocaine addiction continues to be a significant public h

149 Abnormal function in reward circuitry in cocaine addiction could predate drug use as a risk facto

150 to control participants, people with chronic cocaine addiction demonstrate reduced utility PEs in the

151 The lack of medication to treat cocaine addiction desperately calls for a treatment deve

152 There is no effective treatment for cocaine addiction despite extensive knowledge of the neu

153 Methylphenidate has been used to mediate cocaine addiction due to its lower pharmacokinetics, whi

154 There is evidence for sex differences in cocaine addiction from both clinical and preclinical stu

155 armacotherapeutic actions of amphetamine for cocaine addiction go beyond that of replacement therapy.

156 zes GluA2 AMPARs at synapses but its role in cocaine addiction has not been examined.

157 Investigation of the role of stress in cocaine addiction has yielded an efficacious combination

158 isastrous medical and social consequences of cocaine addiction have made the development of an antico

159 armacological approaches to the treatment of cocaine addiction have thus far been disappointing, and

160 e required to link D2R to neuroplasticity in cocaine addiction in females.

161 Cocaine addiction in humans is associated with long-term

162 ce every 2-4 wk, or longer, for treatment of cocaine addiction in humans.

163 raised much interest because of its role in cocaine addiction in preclinical models.

164 uricular acupuncture is widely used to treat cocaine addiction in the United States and Europe.

165 1.6 million people who meet the criteria for cocaine addiction in the United States, and there are cu

166 A new pharmacokinetic approach treating cocaine addiction involves rapidly metabolizing cocaine

167 mechanisms that lead to comorbid anxiety and cocaine addiction, irrespective of which comes first, is

168 Cocaine addiction is a chronic illness characterized by

169 Cocaine addiction is a chronic, relapsing disorder chara

170 Cocaine addiction is a chronically relapsing brain disea

171 Cocaine addiction is a debilitating neuropsychiatric dis

172 Cocaine addiction is a disease characterized by chronic

173 Cocaine addiction is a long-lasting relapsing illness ch

174 Treating cocaine addiction is a major challenge and currently no

175 Cocaine addiction is a major problem for which there is

176 Cocaine addiction is a major public health problem that

177 sequences on behavior.SIGNIFICANCE STATEMENT Cocaine addiction is a neuropsychiatric disorder that is

178 Cocaine addiction is a significant medical and public co

179 etically tractable model system for studying cocaine addiction is already providing new clues that ma

180 Cocaine addiction is associated with altered resting-sta

181 Cocaine addiction is associated with compulsive drug-see

182 Cocaine addiction is associated with disturbed rsFC in s

183 Cocaine addiction is characterized by a gradual loss of

184 Cocaine addiction is characterized by a progressive incr

185 Cocaine addiction is characterized by an impaired abilit

186 Cocaine addiction is characterized by long-lasting vulne

187 Cocaine addiction is characterized by patterns of compul

188 Cocaine addiction is characterized by poor judgment and

189 Cocaine addiction is commonly viewed as a disorder of ne

190 he relationship between anxiety symptoms and cocaine addiction is complicated; anxiety can be both a

191 One of the core symptoms of cocaine addiction is compulsive drug-seeking behavior.

192 ted learning.SIGNIFICANCE STATEMENT Although cocaine addiction is driven in part by the formation of

193 ferences in drug abuse, and a key feature of cocaine addiction is pathologically high motivation for

194 One of the major challenges of cocaine addiction is the high rate of relapse to drug us

195 Cocaine addiction is thought to involve persistent neuro

196 Cocaine addiction is thought to stem, in part, from neur

197 A major goal of treatments for cocaine addiction is to reduce relapse-associated cravin

198 medium spiny neurons (MSNs), one hallmark of cocaine addiction, is independent of DA signaling.

199 Relapse, a major problem in the treatment of cocaine addiction, is proposed to result in part from ne

200 ral and electrophysiological determinants of cocaine addiction liability.

201 bits is not necessary for the development of cocaine addiction-like behavior in rats.SIGNIFICANCE STA

202 s been identified as a predictive factor for cocaine addiction-like behavior.

203 e amygdala of outbred rats with high and low cocaine addiction-like behaviors following prolonged abs

204 molecular adaptations that produce increased cocaine addiction-like behaviors.

205 In a model of cocaine addiction, mAb 15A10 blocked completely the rein

206 Recent evidence suggests that cocaine addiction may involve progressive drug-induced n

207 ining CM with bupropion for the treatment of cocaine addiction may significantly improve outcomes rel

208 t in both rodent and primate striatum, using cocaine addiction mouse models.

209 peractivity disorder, binge eating disorder, cocaine addiction, obesity, and type 2 diabetes.

210 The impact of cocaine addiction on GMV, tested by (1) comparing the CU

211 f acupuncture as a stand-alone treatment for cocaine addiction or in contexts in which patients recei

212 an FDA-approved pharmacotherapy specific for cocaine addiction or overdose.

213 no market-approved medications for treating cocaine addiction or relapse exist, and effective interv

214 nsisted of all adults with a heroin or crack cocaine addiction, or both, who started pharmacological

215 D3/D4 receptors as potential treatments for cocaine addiction, particularly in combination with enri

216 1 receptors may represent a novel target for cocaine addiction pharmacotherapies.

217 edited GluA2(Q) represent a novel target for cocaine addiction pharmacotherapies.

218 Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possib

219 her consideration of PDM as a candidate anti-cocaine addiction pharmacotherapy.

220 dol has been explored as a possible agent in cocaine addiction pharmacotherapy.

221 al responses to cocaine in all phases of the cocaine addiction process (induction, maintenance, and r

222 genetic and neurobiological contributions to cocaine addiction, provides a rapid approach for generat

223 ew cocaine vaccine (dAd5GNE) in antagonizing cocaine addiction-related behaviors in rats.

224 In addition to serving as a therapy for cocaine addiction-related diseases, enhanced bioscavengi

225 rability of impulsive individuals to develop cocaine addiction remain unknown.

226 Cocaine addiction remains a serious problem lacking an e

227 ate how the mPFC is functionally involved in cocaine addiction remains incomplete.

228 ion, a role of the endocannabinoid system in cocaine addiction remains widely inconclusive.

229 Cocaine addiction remains without an effective pharmacot

230 logical basis of sex-specific differences in cocaine addiction resides in the disparate regulation of

231 and, an induced plasticity evoked by chronic cocaine addiction resulted in progressive transcriptiona

232 oimaging studies have shown that people with cocaine addiction retain some degree of control over dru

233 s a key role in determining vulnerability to cocaine addiction, reveal new molecular regulators that

234 sing therapeutic target for the treatment of cocaine addiction, schizophrenia, Parkinson's disease, a

235 ossibility that the behaviors characterizing cocaine addiction, such as craving-induced relapse, may

236 gene and protein expression associated with cocaine addiction suggest the existence of a mechanism t

237 h rate of comorbidity between depression and cocaine addiction suggests shared molecular mechanisms a

238 g why women display a more severe profile of cocaine addiction than men.

239 women experiencing a more severe profile of cocaine addiction than men.

240 lying the vulnerability of impulsive rats to cocaine addiction that localize to the OFC, infralimbic

241 network interactions have been identified in cocaine addiction, the association between these brain n

242 asingly more at risk for the consequences of cocaine addiction, the need to establish better-tailored

243 an established role in preclinical models of cocaine addiction, the translational significance of the

244 RIP as a novel target for the development of cocaine addiction therapeutics.

245 ver, the actual therapeutic use of a CocH in cocaine addiction treatment is limited by its short biol

246 l drug repurposing candidates for opioid and cocaine addiction treatment, bridging the gap between tr

247 orthosteric antagonists/inverse agonists for cocaine addiction treatment.

248 ing candidates for further investigation for cocaine addiction treatment.

249 ed at these complexes may have potential for cocaine addiction treatment.SIGNIFICANCE STATEMENT Toler

250 There is a large unmet medical need for cocaine addiction treatments.

251 Treating cocaine addiction using dopamine replacement strategies,

252 patients with schizophrenia, depression, or cocaine addiction, using functional magnetic resonance i

253 Hence, cocaine addiction vulnerability may be linked to multipl

254 evel effects of methylphenidate; severity of cocaine addiction was assessed by interview and question

255 The results of the study showed that cocaine addiction was associated with a 20% to 22% reduc

256 ocaine-induced increases in actin cycling in cocaine addiction was examined using the reinstatement o

257 velop a pharmacotherapy for the treatment of cocaine addiction, we embarked on synthesizing novel mol

258 ne oxidase inhibitor selegiline for treating cocaine addiction, we required a method for measuring ur